Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kyoshiro Tsuge has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Versatile and Cross-Species Alveolar Type II Cell Isolation Using Humanized Monoclonal Antibody Upifitamab

    by Michael T. Forrester, Shuyu Liu, Kyoshiro Tsuge, Rhianna Lee-Ferris, Krsna Rangarajan, R. Ian Cumming, Khaliun Enkhbayar, Jeremy M. Morowitz, Thomas J. Whitlow, Aleksandra Tata, et al.

    SUMMARY: Alveolar type 2 (AT2) cells are primary adult alveolar stem cells that maintain healthy alveoli. AT2 cell dysfunction is broadly linked to many lung pathologies from emphysema to fibrosis. Isolation of AT2 cells with high purity is therefore central to diagnostic studies, proteomics, transcriptomics and ex vivo experiments that can lead to future AT2 cellular therapies. Current markers for AT2 isolation exhibit various limitations from species-restrictions (e.g., mouse vs human) to limited AT2 specificity, which creates challenges for flow cytometric gating/sorting and application to magnetic-activated cell isolation. While underrepresented in the literature, these bottlenecks have made AT2 cell isolation inherently difficult and slowed AT2 cell research. Here we leverage surface protein-restricted transcriptomics to identify the sodium phosphate transporter NaPi2b (SLC34A2) as a highly specific AT2 cell marker optimally detected with the humanized monoclonal antibody upifitamab. Upifitamab-based labeling of AT2 cells is compatible with flow cytometric or magnetic-activated AT2 isolation and applies to both mouse and human AT2 cells, thus streamlining protocols and circumventing species-specific nuances. AT2 cells obtained with upifitamab can be cultured as organoids, in monolayers or differentiated to AT1 cells. This simplified AT2 isolation approach should overcome several current barriers while facilitating ex vivo studies on alveolar biology and related therapeutic developments.

  • Open Access

    A tonic PDGFA-dependent niche organizer maintains alveolar homeostasis

    by Rebecca Shelley Frabotta, Arvind Konkimalla, Thomas Whitlow, Kyoshiro Tsuge, Shuyu Liu, Michael T. Forrester, Aleksandra Tata, Purushothama Rao Tata

    Tissue homeostasis requires mechanisms that preserve quiescence while allowing rapid activation after injury, but how tissues actively restrain injury responses during homeostasis remains poorly understood. Here we identify alveolar type 1 (AT1) cells as organizers of the distal lung niche through tonic expression of PDGFA, which maintains alveolar fibroblast identity and restrains myofibroblast activation. Cell type-specific ablation revealed that loss of AT1s, but not other major alveolar cell populations, was sufficient to evoke spontaneous fibroblast activation and tissue-wide responses that recapitulate injury. In silico ligand-receptor analysis, ex vivo screening, and conditional genetic models identified AT1-derived PDGFA as a key homeostatic signal. Loss of AT1-derived PDGFA caused spontaneous myofibroblast induction and tissue remodeling, whereas increasing PDGFA promoted fibroblast proliferation while suppressing myofibroblast differentiation. Integrated phosphoproteomic, transcriptomic, and chromatin accessibility analyses showed that PDGFA engages SHP2-ERK signaling, suppresses MRTFA-associated SRF programs, and promotes E2F-associated cell-cycle programs, thereby opposing the pro-fibrotic effects of TGFβ-driven fibroblast activation. Restoring PDGFA signaling abrogates myofibroblast features from human idiopathic pulmonary fibrotic lungs and attenuated fibrotic remodeling in vivo. These findings define a tonic AT1-derived PDGFA signal that maintains alveolar homeostasis and offers a therapeutic target to prevent or revert lung fibrosis.

  • Open Access

    Alveolar Cytochrome P450 Mediates Butylated Hydroxytoluene-Induced Electrophilic Injury and Apoptosis

    by Michael T Forrester, Katherine M Harbaugh, Naoya Miyashita, Kyoshiro Tsuge, Rhianna Lee-Ferris, Jeremy M Morowitz, Aleksandra Tata, Robert M Tighe, Matthew W Foster, Christine E Eyler, et al.

    Butylated hydroxytoluene (BHT) is a synthetic phenolic antioxidant utilized as a preservative in many products from foods to cosmetics. Population-based studies have detected BHT in the vast majority (>90%) of human specimens (serum, urine, fingernails) as well as home dust samples. Thus, BHT constitutes a ubiquitous environmental contaminant without obvious adverse health effects to humans. In contrast, exposure of mice to a single intraperitoneal dose of BHT triggers distal epithelial damage including loss of gas-exchanging alveolar type 1 epithelial cells, thus providing an invaluable tool to study alveolar repair and transient fibrosis. Presently, the molecular basis of BHT lung toxicity remains unknown. To address this, mouse lung single cell transcriptomic data were used to identify cytochrome P450 2B10 (CYP2B10) in AT1 cells as a BHT-activating enzyme. In cell culture systems, expression of CYP2B10 leads to marked BHT sensitization consistent with bioactivation of BHT into a toxic quinone methide. Targeted and proteome-wide experiments identify BHT-induced protein alkylation, DNA damage response, stress kinase activation and intrinsic apoptosis in a CYP2B10-dependent manner. Structure-activity relationship studies reveal the necessity of para-methyl and ortho-t-butyl groups necessary for BHT bioactivation. Our findings elucidate the molecular basis by which BHT is converted from an innocuous antioxidant into a highly toxic quinone methide and identify the first mammalian enzyme known to catalyze BHT bioactivation. Further, CYP2B10-catalyzed BHT bioactivation may provide a strategy for future targeted cell ablation technologies or environmental remediation of BHT.

  • Open Access

    Research on Werner Syndrome: Trends from Past to Present and Future Prospects

    by Kyoshiro Tsuge, Akira Shimamoto

    A rare and autosomal recessive premature aging disorder, Werner syndrome (WS) is characterized by the early onset of aging-associated diseases, including shortening stature, alopecia, bilateral cataracts, skin ulcers, diabetes, osteoporosis, arteriosclerosis, and chromosomal instability, as well as cancer predisposition. WRN, the gene responsible for WS, encodes DNA helicase with a 3′ to 5′ exonuclease activity, and numerous studies have revealed that WRN helicase is involved in the maintenance of chromosome stability through actions in DNA, e.g., DNA replication, repair, recombination, and epigenetic regulation via interaction with DNA repair factors, telomere-binding proteins, histone modification enzymes, and other DNA metabolic factors. However, although these efforts have elucidated the cellular functions of the helicase in cell lines, they have not been linked to the treatment of the disease. Life expectancy has improved for WS patients over the past three decades, and it is hoped that a fundamental treatment for the disease will be developed. Disease-specific induced pluripotent stem (iPS) cells have been established, and these are expected to be used in drug discovery and regenerative medicine for WS patients. In this article, we review trends in research to date and present some perspectives on WS research with regard to the application of pluripotent stem cells. Furthermore, the elucidation of disease mechanisms and drug discovery utilizing the vast amount of scientific data accumulated to date will be discussed.


  • Open Access

    Essential role of prostaglandin E2 and the EP3 receptor in lymphatic vessel development during zebrafish embryogenesis

    by Ryo Iwasaki, Kyoshiro Tsuge, Koichiro Kishimoto, Yuta Hayashi, Takuya Iwaana, Hirofumi Hohjoh, Tomoaki Inazumi, Atsuo Kawahara, Soken Tsuchiya, Yukihiko Sugimoto

    Lymphatic endothelial cells arise from the venous endothelial cells in embryonic lymphatic development. However, the molecular mechanisms remain to be elucidated. We here report that prostaglandin (PG) E2 plays essential roles in the embryonic lymphatic development through the EP3 receptor, one of the PGE2 receptors. Knockdown of the EP3 receptor or inhibition of cyclooxygenases (COX; rate-limiting enzymes for PG synthesis) impaired lymphatic development by perturbing lymphatic specification during zebrafish development. These impairments by COX inhibition were recovered by treatment with sulprostone (EP1/3 agonist). Knockdown of the EP3 receptor further demonstrated its requirement in the expression of sex determining region Y-box 18 (sox18) and nuclear receptor subfamily 2, group F, member 2 (nr2f2), essential factors of the lymphatic specification. The EP3 receptor was expressed in the posterior cardinal vein (region of embryonic lymphatic development) and the adjacent intermediate cell mass (ICM) during the lymphatic specification. COX1 was expressed in the region more upstream of the posterior cardinal vein relative to the EP3 receptor, and the COX1-selective inhibitor impaired the lymphatic specification. On the other hand, two COX2 subtypes did not show distinct sites of expression around the region of expression of the EP3 receptor. Finally, we generated EP3-deficient zebrafish, which also showed defect in lymphatic specification and development. Thus, we demonstrated that COX1-derived PGE2-EP3 pathway is required for embryonic lymphatic development by upregulating the expression of key factors for the lymphatic specification.


  • Molecular mechanisms underlying prostaglandin E2-exacerbated inflammation and immune diseases

    by Kyoshiro Tsuge, Tomoaki Inazumi, Akira Shimamoto, Yukihiko Sugimoto

    Prostaglandins (PGs) are the major lipid mediators in animals and which are biosynthesized from arachidonic acid by the cyclooxygenases (COX-1 or COX-2) as the rate-limiting enzymes. Prostaglandin E2 (PGE2), which is the most abundantly detected PG in various tissues, exerts versatile physiological and pathological actions via four receptor subtypes (EP1–4). Non-steroidal anti-inflammatory drugs, such as aspirin and indomethacin, exert potent anti-inflammatory actions by the inhibition of COX activity and the resulting suppression of PG production. Therefore, PGE2 has been shown to exacerbate several inflammatory responses and immune diseases. Recently, studies using mice deficient in each PG receptor subtype have clarified the detailed mechanisms underlying PGE2-associated inflammation and autoimmune diseases involving each EP receptor. Here, we review the recent advances in our understanding of the roles of PGE2 receptors in the progression of acute and chronic inflammation and autoimmune diseases. PGE2 induces acute inflammation through mast cell activation via the EP3 receptor. PGE2 also induces chronic inflammation and various autoimmune diseases through T helper 1 (Th1)-cell differentiation, Th17-cell proliferation and IL-22 production from Th22 cells via the EP2 and EP4 receptors. The possibility of EP receptor-targeted drug development for the treatment of immune diseases is also discussed.


  • Ligand binding to human prostaglandin E receptor EP4 at the lipid-bilayer interface

    by Yosuke Toyoda, Kazushi Morimoto, Ryoji Suno, Shoichiro Horita, Keitaro Yamashita, Kunio Hirata, Yusuke Sekiguchi, Satoshi Yasuda, Mitsunori Shiroishi, Tomoko Shimizu, et al.

    Prostaglandin E receptor EP4, a G-protein-coupled receptor, is involved in disorders such as cancer and autoimmune disease. Here, we report the crystal structure of human EP4 in complex with its antagonist ONO-AE3-208 and an inhibitory antibody at 3.2 Å resolution. The structure reveals that the extracellular surface is occluded by the extracellular loops and that the antagonist lies at the interface with the lipid bilayer, proximal to the highly conserved Arg316 residue in the seventh transmembrane domain. Functional and docking studies demonstrate that the natural agonist PGE2 binds in a similar manner. This structural information also provides insight into the ligand entry pathway from the membrane bilayer to the EP4 binding pocket. Furthermore, the structure reveals that the antibody allosterically affects the ligand binding of EP4. These results should facilitate the design of new therapeutic drugs targeting both orthosteric and allosteric sites in this receptor family.


  • Olfactory receptor for prostaglandin F2α mediates male fish courtship behavior

    by Yoichi Yabuki, Tetsuya Koide, Nobuhiko Miyasaka, Noriko Wakisaka, Miwa Masuda, Masamichi Ohkura, Junichi Nakai, Kyoshiro Tsuge, Soken Tsuchiya, Yukihiko Sugimoto, et al.

    Pheromones play vital roles for survival and reproduction in various organisms. In many fishes, prostaglandin F2α acts not only as a female reproductive hormone, facilitating ovulation and spawning, but also as a sex pheromone inducing male reproductive behaviors. Here, we unravel the molecular and neural circuit mechanisms underlying the pheromonal action of prostaglandin F2α in zebrafish. Prostaglandin F2α specifically activates two olfactory receptors with different sensitivities and expression in distinct populations of ciliated olfactory sensory neurons. Pheromone information is then transmitted to two ventromedial glomeruli in the olfactory bulb and further to four regions in higher olfactory centers. Mutant male zebrafish deficient in the high-affinity receptor exhibit loss of attractive response to prostaglandin F2α and impairment of courtship behaviors toward female fish. These findings demonstrate the functional significance and activation of selective neural circuitry for the sex pheromone prostaglandin F2α and its cognate olfactory receptor in fish reproductive behavior.


  • Molecular and pharmacological characterization of zebrafish ‘contractile’ and ‘inhibitory’ prostanoid receptors

    by Ryo Iwasaki, Kyoshiro Tsuge, Kazushi Morimoto, Tomoaki Inazumi, Osamu Kawahara, Atsuo Kawahara, Soken Tsuchiya, Yukihiko Sugimoto


  • Molecular and pharmacological characterization of zebrafish ‘relaxant’ prostanoid receptors

    by Kyoshiro Tsuge, Ryo Iwasaki, Kazushi Morimoto, Tomoaki Inazumi, Osamu Kawahara, Atsuo Kawahara, Soken Tsuchiya, Yukihiko Sugimoto